JDRF Blog
What We Can Be Proud of in 2022
There is tremendous progress in accelerating cures, improving lives, and advocating for people with T1D and their loved ones over the past year.
Read More About What We Can Be Proud of in 2022
FDA Approves Tzield™—A Watershed Moment for the T1D Community
JDRF celebrates the FDA approval of Tzield, the first disease-modifying therapy to delay clinical T1D in people at risk of developing the disease.
Read More About FDA Approves Tzield™—A Watershed Moment for the T1D Community
The T1D Index: A First-of-its-Kind Lifesaving Tool
The T1D Index is a first-of-its-kind data simulation tool that provides the most accurate and comprehensive global picture of type 1 diabetes in history.
Read More About The T1D Index: A First-of-its-Kind Lifesaving Tool
JDRF Timeline: Stem Cell Therapies
Stem cells have the potential to lead to treatments for type 1 diabetes, but it has taken JDRF more than 20 years to get to this point.
Read More About JDRF Timeline: Stem Cell TherapiesRecent Articles
Sign up for our monthly Research Newsletter, The Pipeline, to stay up to date on the latest and greatest in T1D science.
By clicking Sign Up, I agree to the JDRF Privacy Policy. I also agree to receive emails from JDRF and I understand that I may opt out of JDRF subscriptions at any time.